Synthesis and In Vitro Characterization of Glycopeptide Drug Candidates Related to PACAP


Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
14 Aug 2021
Historique:
received: 22 07 2021
revised: 10 08 2021
accepted: 11 08 2021
entrez: 27 8 2021
pubmed: 28 8 2021
medline: 25 9 2021
Statut: epublish

Résumé

The search for efficacious treatment of neurodegenerative and progressive neuroinflammatory diseases continues, as current therapies are unable to halt or reverse disease progression. PACAP represents one potential therapeutic that provides neuroprotection effects on neurons, and also modulates inflammatory responses and circulation within the brain. However, PACAP is a relatively long peptide hormone that is not trivial to synthesize. Based on previous observations that the shortened isoform PACAP

Identifiants

pubmed: 34443519
pii: molecules26164932
doi: 10.3390/molecules26164932
pmc: PMC8401035
pii:
doi:

Substances chimiques

Glycopeptides 0
Neuroprotective Agents 0
Peptide Fragments 0
Peptide Hormones 0
Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I 0
Receptors, Vasoactive Intestinal Peptide, Type II 0
Receptors, Vasoactive Intestinal Polypeptide, Type I 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NINDS NIH HHS
ID : R01NS091238
Pays : United States

Références

Peptides. 2015 Apr;66:26-42
pubmed: 25698233
J Med Chem. 2009 May 28;52(10):3308-16
pubmed: 19413310
J Neuroinflammation. 2004 Jul 30;1(1):14
pubmed: 15285801
Bioorg Med Chem. 2018 Jun 1;26(10):2700-2707
pubmed: 28720325
Br J Oral Maxillofac Surg. 2012 Jun;50(4):298-308
pubmed: 21530028
Nat Rev Neurol. 2014 Apr;10(4):217-24
pubmed: 24638131
Neuropsychopharmacology. 2012 Jan;37(1):213-46
pubmed: 21956442
J Pharmacol Exp Ther. 2008 Sep;326(3):939-48
pubmed: 18511649
Future Med Chem. 2012 Feb;4(2):205-26
pubmed: 22300099
Eur J Biochem. 1992 Jul 1;207(1):239-46
pubmed: 1321043
Nat Rev Immunol. 2017 Jan;17(1):49-59
pubmed: 27916979
Regul Pept. 1996 Apr 23;62(2-3):125-30
pubmed: 8795075
NPJ Parkinsons Dis. 2018 Jul 10;4:21
pubmed: 30003140
Regul Pept. 2006 Nov 15;137(1-2):4-19
pubmed: 17027094
J Physiol. 2004 Jan 15;554(Pt 2):519-28
pubmed: 14578481
Chem Soc Rev. 2016 Feb 7;45(3):631-54
pubmed: 26612670
Lancet Neurol. 2009 Apr;8(4):382-97
pubmed: 19296921
Curr Top Med Chem. 2019;19(16):1399-1417
pubmed: 31284862
Nat Rev Drug Discov. 2021 Apr;20(4):309-325
pubmed: 33536635
J Pharmacol Exp Ther. 2019 Apr;369(1):9-25
pubmed: 30709867
Front Chem. 2015 Jun 24;3:40
pubmed: 26157795
Exp Neurol. 2017 Dec;298(Pt A):31-41
pubmed: 28844606
Neurotox Res. 2011 Apr;19(3):423-34
pubmed: 20422475
Mol Pharmacol. 1992 Aug;42(2):347-55
pubmed: 1325033
Regul Pept. 2004 Dec 15;123(1-3):69-75
pubmed: 15518895
J Pharmacol Exp Ther. 1993 Nov;267(2):690-6
pubmed: 8246142
Neurosci Lett. 2012 Dec 7;531(2):99-103
pubmed: 23127847
Chem Biol Drug Des. 2007 Jan;69(1):41-7
pubmed: 17313456
Nat Rev Neurosci. 2007 Jan;8(1):57-69
pubmed: 17180163
Circ Res. 2017 Feb 3;120(3):439-448
pubmed: 28154096
FASEB J. 2006 Mar;20(3):512-4
pubmed: 16401644
Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6398-403
pubmed: 11972030
Drug Discov Today. 2013 Sep;18(17-18):807-17
pubmed: 23726889
Regul Pept. 2004 Dec 15;123(1-3):85-94
pubmed: 15518897
Pharmacol Rev. 2009 Sep;61(3):283-357
pubmed: 19805477
Pharmacol Rep. 2005 May-Jun;57(3):307-20
pubmed: 15985713
Peptides. 2015 Oct;72:16-9
pubmed: 25805003
Acta Pharmacol Sin. 2012 Mar;33(3):300-11
pubmed: 22266723
Peptides. 2020 Sep;131:170369
pubmed: 32673700
Chem Sci. 2016 Apr 21;7(4):2492-2500
pubmed: 28660018
Science. 2016 Aug 19;353(6301):777-83
pubmed: 27540165
Biochim Biophys Acta Gen Subj. 2019 Nov;1863(11):129410
pubmed: 31401178
Curr Pharm Des. 2011;17(10):1002-24
pubmed: 21524253
J Neurosurg. 2018 Apr 1;:1-18
pubmed: 29701556
Peptides. 2011 Jun;32(6):1207-16
pubmed: 21514338
Carbohydr Res. 2012 Apr 1;351:121-5
pubmed: 22342206
Front Pharmacol. 2013 Dec 13;4:155
pubmed: 24379782
Biochem Pharmacol. 2011 Feb 15;81(4):552-61
pubmed: 21114961
J Pept Sci. 1999 Sep;5(9):403-9
pubmed: 10526883
Trends Pharmacol Sci. 2014 Jan;35(1):12-22
pubmed: 24359917
J Med Chem. 2014 Mar 27;57(6):2237-46
pubmed: 24576160
Int J Mol Sci. 2020 Dec 22;22(1):
pubmed: 33374986

Auteurs

Christopher R Apostol (CR)

Department of Chemistry and Biochemistry, BIO5, The University of Arizona, 1306 E. University Blvd, Tucson, AZ 85721, USA.

Parthasaradhireddy Tanguturi (P)

Department of Pharmacology, College of Medicine, The University of Arizona, 1501 N. Campbell Ave, Tucson, AZ 85724, USA.

Lajos Z Szabò (LZ)

Department of Chemistry and Biochemistry, BIO5, The University of Arizona, 1306 E. University Blvd, Tucson, AZ 85721, USA.

Daniel Varela (D)

Facultat de Quìmica Tarragona, Universitat Rovera I Virgili, 43007 Barcelona, Spain.

Thiago Gilmartin (T)

Facultat de Quìmica Tarragona, Universitat Rovera I Virgili, 43007 Barcelona, Spain.

John M Streicher (JM)

Department of Pharmacology, College of Medicine, The University of Arizona, 1501 N. Campbell Ave, Tucson, AZ 85724, USA.

Robin Polt (R)

Department of Chemistry and Biochemistry, BIO5, The University of Arizona, 1306 E. University Blvd, Tucson, AZ 85721, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH